EMA Says To Facilitate Increasing Supply Of Ozempic, Novo Nordisk Decided To Temporarily Reduce The Supply Of Victoza; Novo Nordisk Informed The Shortage Situation For Ozempic And Victoza Will Deteriorate In Q4 2023
Portfolio Pulse from Benzinga Newsdesk
The European Medicines Agency (EMA) has announced that Novo Nordisk will temporarily reduce the supply of Victoza to facilitate an increased supply of Ozempic. Novo Nordisk has informed that the shortage of both Ozempic and Victoza is expected to worsen in Q4 2023.
November 21, 2023 | 2:20 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Novo Nordisk is expected to face a shortage of Ozempic and Victoza, which may impact revenue and stock performance in the short term.
The announcement by the EMA indicates a supply chain issue for Novo Nordisk's products Ozempic and Victoza. As these are significant products for the company, the expected shortage could lead to a decrease in sales revenue, which may negatively affect the stock price in the short term. Investors may react to the news of the shortage by adjusting their expectations for the company's performance in the upcoming quarter.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90